NCT01451086View on ClinicalTrials.gov

Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy
Interventions
BIOLOGICAL

vaccine made by Beijing Minhai Biotechnology Co., Ltd

Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.

BIOLOGICAL

vaccine made by Chengdu Institute of Biological Products

Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

Sponsors
All Listed Sponsors
collaborator

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK